Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MPL | P40238 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24710395 | 0.90 | ALDH1A1 (0.33) | ALDH1A1KDM4EHSD17B10PKMHPGD | |
| SCHEMBL31345743 | 0.83 | ESR2 (0.41) | ALDH1A1KDM4EHSD17B10PKMHPGD | |
| SCHEMBL28567219 | 0.83 | ESR2 (0.41) | ALDH1A1KDM4EHSD17B10PKMHPGD | |
| SCHEMBL19878460 | 0.83 | ALDH1A1 (0.36) | ALDH1A1KDM4EHSD17B10PKMHPGD | |
| SCHEMBL5366083 | 0.83 | ALDH1A1 (0.48) | ALDH1A1KDM4EHSD17B10PKMHPGD | |
| SCHEMBL309479 | 0.82 | ALDH1A1 (0.52) | ALDH1A1KDM4EHSD17B10PKMHPGD | |
| SCHEMBL5958675 | 0.82 | ALDH1A1 (0.41) | ALDH1A1KDM4EHSD17B10PKMHPGD | |
| Bromide SCHEMBL3161327 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10PKMHPGD | |
| Hydrochloric Acid SCHEMBL4381686 | 0.80 | IDO1 (0.52) | ALDH1A1KDM4EHSD17B10PKMHPGD | |
| SCHEMBL24711096 | 0.79 | ALDH1A1 (0.34) | ALDH1A1KDM4EHSD17B10PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500257-B1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20240287081-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-08-29 | — | — | US | disclosed |
| WO-2022261352-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261352-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3500257-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | Icahn School of Medicine at Mount Sinai (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | ALDH1A1 3660/4885KDM4E 573/4885HSD17B10 3222/4885 |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | ALDH1A1 3660/4885KDM4E 573/4885HSD17B10 3222/4885 |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | ALDH1A1 3660/4885KDM4E 573/4885HSD17B10 3222/4885 |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | ALDH1A1 3660/4885KDM4E 573/4885HSD17B10 3222/4885 |
| US-20240287081-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | PPARD, PFAS, FOLR2 | ALDH1A1 772/4885KDM4E 3743/4885HSD17B10 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.